GlassScriptPhysician profile
Randi J Votava
NPI 1144407321
$2,830.77
in general payments reported to CMS, 2019-2025
33 companies · $2,652 in 2025
The $2,652 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $179 · 2025: $2,652.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,743 · Education: $87.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,743.28 |
| Education | $87.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $424.47 | 2024-2025 | Fintepla, Nayzilam, Rystiggo |
| Abbvie INC. | $278.88 | 2025 | |
| Novartis Pharmaceuticals Corporation | $252.07 | 2024-2025 | |
| Eisai INC. | $251.41 | 2024-2025 | |
| Pfizer INC. | $161.25 | 2025 | |
| Ani Pharmaceuticals, INC. | $147.28 | 2024-2025 | Purified Cortrophin Gel |
| Emd Serono, INC. | $128.73 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $116.29 | 2025 | Austedo Xr |
| Neurocrine Biosciences, INC. | $103.66 | 2024-2025 | Ingrezza |
| Lundbeck LLC | $98.80 | 2025 | Vyepti, Rexulti |
| Xeris Pharmaceuticals, INC. | $94.24 | 2025 | Keveyis |
| Tg Therapeutics, INC. | $67.14 | 2025 | |
| Vanda Pharmaceuticals INC. | $65.74 | 2025 | Ponvory |
| Axsome Therapeutics, INC. | $65.01 | 2025 | Symbravo |
| Aucta Pharmaceuticals, INC. | $62.87 | 2024-2025 | Motpoly Xr |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Catalyst Pharmaceuticals, INC. | $49.08 | 2025 | |
| Amneal Pharmaceuticals LLC | $42.58 | 2025 | Crexont |
| Argenx US, INC. | $42.53 | 2025 | Vyvgart Hytrulo |
| Biogen, INC. | $39.16 | 2025 | Skyclarys, Tysabri |
| Janssen Biotech, INC. | $37.69 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.76 | 2025 | Hyqvia |
| Neurelis, INC. | $32.22 | 2024-2025 | Valtoco |
| Lilly USA, LLC | $31.77 | 2025 | Kisunla |
| Genzyme Corporation | $28.94 | 2025 | |
| Sk Life Science, INC. | $25.75 | 2025 | |
| Harmony Biosciences LLC | $25.05 | 2025 | |
| Acadia Pharmaceuticals INC | $24.89 | 2025 | Nuplazid |
| Genentech USA, INC. | $18.40 | 2025 | Ocrevus Zunovo |
| Collegium Pharmaceutical, INC. | $18.15 | 2025 | Belbuca |
| Medtronic, INC. | $16.71 | 2024 | Intellis Adaptivestim |
| Tanabe Pharma America, INC. | $16.21 | 2025 | Radicava |
| Alexion Pharmaceuticals, INC. | $14.80 | 2025 | Ultomiris |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $13.24 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randi Votava listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.